Ann: Trading Halt, page-21

First 21 Last

Share
Profile

Follow
Capsicumz

126 Posts.

27

28/11/19

15:17

Post #: 41688160
Share

Originally posted by country bob: ↑

Capsicumz, there is a lot of history here. We keep being told to look to the future - the future is getting further and further and further away IMO.

I have copied and pasted the following from the other conversation (Chairman's Address to Shareholders). It is not my intention to be a naysayer, rather just to point out that NOTHING happens quickly with NET.

I've just been reading the chairman's presentation closely (I did dial in to the phone hook-up. What an absolute joke!!! NET management should simply be embarrassed that they can't even organise that).

If I'm reading the presentation correctly:
- 2020 the INTRODUCTION of products will be accelerated (note INTRODUCTION)
- 2021 there will be more product evolution and growth
- 2022 chance of some profit.

So, my prediction that the NET share price won't really do anything until early 2021 now seems optimistic. That is incredibly disappointing. They are forever hardening and productising, expanding, evolving, iterating, improving, branching and increasing, qualifying and testing, piloting and maximising. They are doing so many things - EXCEPT ONE - making meaningful sales. Yes, isoftstone are taking 100,000 a month but that constitutes the total expected income for 2020 of $10 million. No other sales predicted. I was laughed at when I suggested they should prove sales before setting up for world domination, but world domination is what they are pursuing. Now they are going to raise another $30 million to spend on development and getting market ready. Once again their greatest strength is being able to suck money out of the world despite years and years of developing and testing and piloting and partnership agreements and reseller agreements and all sorts of other activity, except sales. This is about the third or fourth time this has happened.

IMO they can announce all the good news they like (and they have announced plenty over the last 6 years - good news followed by more good news) but until they SHOW US THE MONEY this is going nowhere.

Well done to all the clever people who bought at 2 cents. For anyone considering buying in now be prepared for a very long wait..................

Expand

I can empathise with you mate as it doesn't sound like you have bought NET at a lower share price than what it is currently.
No one has a crystal ball but just hang in there as further positive announcements could be just around the corner.

NET Price at posting: 16.0¢ Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

IRE

Iress runs 'hot' for Wealth Within's stock tips

Failure to report prompts ASX to impose multiple company suspensions

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 3 more messages in this thread...

First 21 Last

Add NET (ASX) to my watchlist

(20min delay)
Last 0.3¢		Change 0.000(0.00%)		Mkt cap ! $11.63M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Ann: Trading Halt, page-21

Iress runs 'hot' for Wealth Within's stock tips

Failure to report prompts ASX to impose multiple company suspensions

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Featured News

Ann: Trading Halt, page-21

Top Stories

Iress runs 'hot' for Wealth Within's stock tips

Failure to report prompts ASX to impose multiple company suspensions

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Featured News